Vitiligo

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

The first subject has been dosed in a phase 2b trial evaluating VYN201 for the treatment of active or stable nonsegmental vitiligo.

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.

SAN DIEGO — Patients with nonsegmental vitiligo continually improved with upadacitinib treatment up to 1 year, according to a speaker at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — In patients with active nonsegmental vitiligo, ritlecitinib monotherapy or paired with twice weekly narrowband ultraviolet B phototherapy improved facial and total body repigmentation, according to a speaker here.

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

VYN201 showed positive effects on biomarkers of vitiligo in a phase 1b trial, VYNE Therapeutics announced in a press release.

VYNE Therapeutics has announced its third-quarter 2023 financial results and business updates, according to a company press release.